PELICAN-IPC 2015–016/Oncodistinct-003: A randomized non-comparative phase II study of pembrolizumab in combination with neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer
European Journal of Cancer · 2026-12 · 249 · 117816
DOI: 10.1016/j.ejca.2026.117816 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2026-12. Verfasst von Alexandre de Nonneville und 16 weiteren Autor:innen. Beteiligte Einrichtung: Aix-Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MSD France SAS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Aix-Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France.
- Department of Medical Oncology, Institut Curie, St Cloud, France.
- Direction of Clinical Research and Investigation, Biostatistics and Methodology Unit, Institut Paoli-Calmettes, France.
- Department of medical oncology, Oncopole Claudius Regaud, IUCT-O, Toulouse, France.
- Department of Medical Oncology, Centre François Baclesse, Caen, France.
- Medical Oncology Department, Paul Strauss Cancer Centre, Strasbourg, France.
Förderung
- MSD France SAS
Zitieren
APA
de Nonneville, A., Lerebours, F., Zemmour, C., Dalenc, F., Levy, C., Petit, T., Leheurteur, M., Pierga, J. Y., Bachelot, T., Ladoire, S., Viret, F., Almeida, L. L., Kaya, M., Boher, J. M., Bertucci, F., Charafe, E., & Gonçalves, A. (2026). PELICAN-IPC 2015–016/Oncodistinct-003: A randomized non-comparative phase II study of pembrolizumab in combination with neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer. European Journal of Cancer, 249, 117816. https://doi.org/10.1016/j.ejca.2026.117816
Vancouver
de Nonneville A, Lerebours F, Zemmour C, Dalenc F, Levy C, Petit T, et al. PELICAN-IPC 2015–016/Oncodistinct-003: A randomized non-comparative phase II study of pembrolizumab in combination with neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer. European Journal of Cancer. 2026;249:117816. doi:10.1016/j.ejca.2026.117816
BibTeX
@article{deNonneville2026,
author = {de Nonneville, Alexandre and Lerebours, Florence and Zemmour, Christophe and Dalenc, Florence and Levy, Christelle and Petit, Thierry and Leheurteur, Marianne and Pierga, Jean-Yves and Bachelot, Thomas and Ladoire, Sylvain and Viret, Frédéric and Almeida, Leonor Lopez and Kaya, Muge and Boher, Jean-Marie and Bertucci, François and Charafe, Emmanuelle and Gonçalves, Anthony},
title = {PELICAN-IPC 2015–016/Oncodistinct-003: A randomized non-comparative phase II study of pembrolizumab in combination with neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer},
journal = {European Journal of Cancer},
year = {2026},
volume = {249},
pages = {117816},
doi = {10.1016/j.ejca.2026.117816}
}
EUVIMED